Tempus AI (TEM) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- -$0.04
- Estimate
- -$0.15
- Surprise
- +73.6%
- Revenue (period 2026-06-30)
- $382.5M
- Score today
- 4.7/10
Revenue source: xbrl.
How the report landed
Tempus AI (TEM) reported a narrower loss than forecast — adjusted EPS of -$0.04 against the -$0.15 estimate (a 73.6% beat on a still-unprofitable quarter).
Where TrendMatrix's rating stands now
TrendMatrix currently rates TEM Sell at 4.7/10; no pre/post engine snapshot brackets this report.
4 of the last 4 quarters beat the estimate; this quarter's +73.6% surprise compares with a +42.1% four-quarter average. Next scheduled report: 2026-11-03.
What argues against it
- Concentration risk — Product: oncology and hereditary tests (74.0%)
- Concentration risk — Supplier: sole suppliers
- Target reached (-25.0% upside)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $82.24
- Price target
- $94.58
- Stop
- $76.48
- Upside to target
- +15.0%
Risk check: RSI 74 — a level conventionally read as overbought; gains at these levels often lean on momentum; trading volume is running 1.6× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-09-25 — shown for context, not personalized investment advice.
TEM at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Health Information Services
- Market cap
- $13.82B
- P/E (fwd)
- -9432.3
- 52-week range
- $40.77–$104.32
- Off 52-week high
- 21.2%
- RSI (14)
- 74
- Volume vs avg
- 1.55×
- Score today
- 4.7/10